- Home
- TLSI vs DOUG Comparison
TLSI vs DOUG Comparison
Compare TLSI & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLSI | DOUG |
|---|---|---|
| Founded | 2010 | 1911 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.3M | 219.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TLSI | DOUG |
|---|---|---|
| Price | $6.10 | $2.39 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $11.50 | N/A |
| AVG Volume (30 Days) | 213.7K | ★ 379.2K |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $40,207,000.00 | ★ $1,030,928,000.00 |
| Revenue This Year | $55.06 | $17.61 |
| Revenue Next Year | $46.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 49.52 | 6.67 |
| 52 Week Low | $3.42 | $1.48 |
| 52 Week High | $7.95 | $3.20 |
Technical Indicators
Market Signals| Indicator | TLSI | DOUG |
|---|---|---|
| Relative Strength Index (RSI) | 43.47 | 43.96 |
| Support Level | $5.60 | $2.23 |
| Resistance Level | $7.20 | $2.43 |
| Average True Range (ATR) | 0.47 | 0.10 |
| MACD | -0.21 | -0.01 |
| Stochastic Oscillator | 22.77 | 40.00 |
Price Performance
Historical ComparisonAbout TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.